Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Sun Pharmaceutical Industries, Inc.
- Study ID
- NCT07133308
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- Deuruxolitinib — DRUGDeuruxolitinib will be dosed orally as tablets at a dose of 8 mg
- Placebo — DRUGDeuruxolitinib matching placebo will be dosed orally as tablets
Study Details
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
Key Dates
- Start date
- Aug 5, 2025
- Status verified
- Aug 2025
- Primary completion
- May 31, 2028
- Completion
- May 31, 2028
Study Design
- Enrollment
- 355 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment Period: Deuruxolitinib 8 mgDeuruxolitinib tablets, orally, twice daily (BID) for up to 24 weeks
- Placebo Comparator: Treatment Period: PlaceboDeuruxolitinib-matched placebo tablets, orally, BID for up to 24 weeks
- Experimental: Open-Label Extension: Deuruxolitinib 8 mg BIDDeuruxolitinib tablets, orally, BID for up to 52 weeks
Primary Outcome Measure
Percentage of subjects achieving an absolute Severity of Alopecia Tool (SALT) score ≤20 [ Time Frame: Week 24 ]
Central Contacts
- Head Regulatory Affairs9122 66455645
Locations (54)
Find similar trials in Birmingham, AL
By research site
Total Skin And Beauty Dermatology Center· Birmingham, ALAvacare - Cct Research - Center For Dermatology And Plastic Surgery· Scottsdale, AZDermatology Trial Associates· Bryant, ARKern Research Inc.· Bakersfield, CACenter For Dermatology Clinical Research Inc.· Fremont, CADermatology Research Associates· Los Angeles, CA
Related Studies
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Regeneron AA Multicenter (Dupilumab)PHASE2 · Recruiting · Emma Guttman · Irvine, California
- Dupilumab in the Treatment of Pediatric Alopecia AreataPHASE2 · Recruiting · Icahn School of Medicine at Mount Sinai · Irvine, California
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataPHASE3 · Recruiting · AbbVie · Birmingham, Alabama